Results 151 to 160 of about 224,020 (260)

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto   +20 more
wiley   +1 more source

Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas

open access: yesAdvanced Science, EarlyView.
Multiomics integration analysis reveals the “cystic fluid–tumor cell” metabolic coupling that mediates active choline/ethanolamine uptake of tumor cells from cystic fluid and PC/PE synthesis pathways reprogramming that mediating autophagy pathway activation within ACP. ABSTRACT Adamantinomatous craniopharyngioma (ACP), a benign yet highly recurrent and
Dongting Chen   +9 more
wiley   +1 more source

The impact of JAK2<sup>V617F</sup> variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. [PDF]

open access: yesBr J Haematol
Brown R   +13 more
europepmc   +1 more source

Cytoprotection Concepts for Ischemic Stroke in the Recanalization Era

open access: yesAdvanced Science, EarlyView.
This review provides detailed information on modern cytoprotective strategies for ischemic stroke in the context of recanalization therapies. It derives their rationale based on contemporary knowledge of stroke pathophysiology and discusses the role of advanced imaging approaches as well as concepts for novel clinical trial designs.
Johannes Boltze, Marc Fisher
wiley   +1 more source

Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A. [PDF]

open access: yesPathol Oncol Res
Ferenczi K   +6 more
europepmc   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

open access: yesAdvanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang   +8 more
wiley   +1 more source

Non‐Targeting shRNA‐Encoded Plasmid DNA Enhances Protective Immunity Through RIDD‐RIG‐I Signaling Pathway in the Zika Virus Animal Model

open access: yesAdvanced Science, EarlyView.
We present a novel DNA vaccine platform featuring intrinsic, non‐targeting dsRNA that significantly enhances immune responses by activating the regulated IRE1‐dependent decay‐RIG‐I signaling pathway. This research elucidates a previously uncharacterized mechanism for dsRNA‐mediated innate immune activation.
Min‐Syuan Huang   +10 more
wiley   +1 more source

Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment. [PDF]

open access: yesJ Virol
Ding Y   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy